| Ytd | -26.74% | |
| 1y | 7.03% |
| Open | 1.38 | Prev Close | 1.38 | Low | 1.34 | High | 1.40 | Mkt Cap | 425.84M |
| Vol | 4.96M | Avg Vol | 6.56M | EPS | -0.42 | P/E | N/A | Forward P/E | -2.84 |
| Beta | 2.01 | Short Ratio | 4.46 | Inst. Own | 84.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 1.34 | 200-d Avg | 1.60 | 1yr Est | 3.02 |
PACB News
Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indica
Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthc
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1
UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and low
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition rais
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced posi
Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, inclu
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to of
Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 reven
Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
Pacific Biosciences of California NASDAQ: PACB reported second-quarter 2026 revenue of $39 million,
On July 30, 2026, the Board of Directors (the "Board") of the Company approved a restructuri
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.14 per share in line w
Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million
Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of hi
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.14) per share which missed the an
MENLO PARK, Calif. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASD
MENLO PARK, Calif. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financi
Vega SPRQ-Nx chemistry to deliver up to 90 Gb per run at 40% lower cost per gigabase, with single-sh
McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs,
On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,50
Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level predict
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and
Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
The protocol will be formally presented at the upcoming American Association for Cancer Research (AA
Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to U
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, tod
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno
PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today ann
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, ann
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and
Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral
Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overw
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno